Consistent with our findings with breast cancer cells, depletion of IKZF1 (Fig. 5U-V, S7H-J) or lenalidomide treatment (Fig. 5W-Y) greatly reduced the number of CTCs produced from footpad-injected B16F10 cells without affecting the growth of the primary melanoma. Here, IKZF1 is linked to melanoma.